Liu, Bin; Meng, Xiang; Ma, Yanfang; Li, Huizhen; Liu, Yuqi; Shi, Nannan; Chen, Yaolong; Wang, Yanping; Lu, Cheng published the artcile< Clinical safety of total glucosides of paeony adjuvant therapy for rheumatoid arthritis treatment: a systematic review and meta-analysis>, Electric Literature of 112-63-0, the main research area is meta analysis methotrexate antiinflammatory rheumatoid arthritis; Adjuvant therapy; Clinical safety; Meta-analysis; Rheumatoid arthritis; Systematic review; Total glucosides of paeony.
Total glucosides of paeony (TGP), an active compound extracted from the roots of Paeonia lactiflora Pallas, has been increasingly used as the adjunctive therapy for rheumatoid arthritis (RA) patients. Though TGP could mitigate the unanticipated adverse effects during the conventional treatment of RA, high-quality evidence-based meta-anal. data on this subject are still insufficient. The objective of this study is to evaluate the clin. safety of TGP adjuvant therapy in the RA treatment. PubMed, EMBASE, Web of Science, China Network Knowledge Infrastructure (CNKI), SinoMed and WanFang Data were retrieved for randomized controlled trials (RCTs) and cohort study about TGP adjuvant therapy in patients with RA up to 28 Jan. 2021. Literatures with eligibility criteria and information were screened and extracted by two researchers independently. The RevMan5.3 software was used for data anal. with effect estimates as risk ratio (RR) with 95% confidence interval (CI). A total of 39 studies involving 3680 RA participants were included. There were 8 comparisons: TGP plus methotrexate (MTX) therapy vs. MTX therapy, TGP plus leflunomide (LEF) therapy vs. LEF therapy, TGP plus MTX and LEF therapy vs. MTX plus LEF therapy, TGP plus tripterygium glycosides (TG) therapy vs. TG therapy, TGP plus meloxicam (MLX) therapy vs. MLX therapy and TGP plus sulfasalazine (SSZ) therapy vs. SSZ therapy, TGP plus iguratimod (IGU) therapy vs. IGU therapy, TGP plus prednisone acetate tablets (PAT) therapy vs. PAT therapy. The meta-anal. results showed that the occurrence of hepatic adverse effect (RR = 0.31, 95% CI = 0.23-0.41, P < 0.00001) and leukopenia (RR = 0.41, 95% CI = 0.26-0.66, P = 0.0002) in TGP adjuvant therapy was significant decreased compared with non-TGP therapy. However, only TGP plus LEF therapy (RR = 0.22, 95% CI = 0.08-0.60, P = 0.003) and TGP plus MTX and LEF therapy (RR = 0.31, 95% CI = 0.22-0.42, P < 0.00001) had statistical difference in the subgroups of hepatic adverse effect. In leukopenia, TGP plus MTX and LEF therapy (RR = 0.47, 95% CI = 0.25-0.87, P = 0.02) had statistical difference. This meta-anal. indicated that TGP adjuvant therapy might alleviate the incidence of hepatic adverse effect and leukopenia for the RA treatment compared to non-TGP therapy. The clin. safety of TGP adjuvant therapy warrant further investigation in exptl. studies. BMC Complementary Medicine and Therapies published new progress about Anti-inflammatory agents. 112-63-0 belongs to class esters-buliding-blocks, and the molecular formula is C19H34O2, Electric Literature of 112-63-0.
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics